A detailed history of New Edge Advisors, LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 250 shares of PYXS stock, worth $422. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 250 -0.0%
Holding current value
$422
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$1.4 - $2.09 $2,158 - $3,222
-1,542 Reduced 86.05%
250 $0
Q2 2023

Aug 14, 2023

BUY
$2.46 - $4.07 $3,793 - $6,275
1,542 Added 616.8%
1,792 $4,000
Q1 2023

May 12, 2023

BUY
$1.38 - $6.0 $345 - $1,500
250 New
250 $1,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $59.3M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.